Literature DB >> 16964826

Investigation of baseline susceptibility to protease inhibitors in HIV-1 subtypes C, F, G and CRF02_AG.

Ana B Abecasis1, Koen Deforche, Lee T Bacheler, Paula McKenna, Ana Patricia Carvalho, Perpétua Gomes, Anne-Mieke Vandamme, Ricardo Jorge Camacho.   

Abstract

OBJECTIVE: To compare baseline susceptibility to protease inhibitors among HIV-1 isolates of subtypes C, F, G and CRF02_AG, and to identify polymorphisms that determine the differences in susceptibility.
METHODS: A total of 42 samples of drug-naive patients infected with subtypes G (n=19), CRF02_AG (n = 10), F (n = 6) and C (n = 7) were phenotyped and genotyped with the Antivirogram and the ViroSeq 2.0 genotyping system, respectively. A Bayesian network approach was used for a preliminary analysis of the collected data and the dependencies indicated by the network were statistically confirmed.
RESULTS: CRF02_AG samples were found to be more susceptible to nelfinavir and ritonavir than other subtypes. Hypersusceptibility to these drugs was associated with the 70R polymorphism. 37D/S/T was associated with reduced susceptibility to indinavir and 89M with reduced susceptibility to lopinavir. Susceptibility to tipranavir was the lowest among the subtype F samples and the highest for subtype G samples, with samples carrying 57R being more susceptible than samples carrying 57K.
CONCLUSIONS: Our study suggests that there are baseline susceptibility differences between subtypes and these differences are due to naturally occurring polymorphisms in these subtypes. The predictive value for phenotype of these polymorphisms was even valid in subtypes where these polymorphisms are less prevalent. Taking into account such polymorphisms should improve current algorithms for interpretation of genotyping results in a subtype-independent way.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16964826

Source DB:  PubMed          Journal:  Antivir Ther        ISSN: 1359-6535


  19 in total

Review 1.  Human immunodeficiency virus type 1 subtype distribution in the worldwide epidemic: pathogenetic and therapeutic implications.

Authors:  L Buonaguro; M L Tornesello; F M Buonaguro
Journal:  J Virol       Date:  2007-07-18       Impact factor: 5.103

2.  Structure of the unbound form of HIV-1 subtype A protease: comparison with unbound forms of proteases from other HIV subtypes.

Authors:  Arthur H Robbins; Roxana M Coman; Edith Bracho-Sanchez; Marty A Fernandez; C Taylor Gilliland; Mi Li; Mavis Agbandje-McKenna; Alexander Wlodawer; Ben M Dunn; Robert McKenna
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2010-02-12

3.  Comparison of drug resistance scores for tipranavir in protease inhibitor-naive patients infected with HIV-1 B and non-B subtypes.

Authors:  Martin Stürmer; Christoph Stephan; Peter Gute; Gaby Knecht; Markus Bickel; Hans-Reinhard Brodt; Hans W Doerr; Lutz Gürtler; Pierre Lecocq; Margriet van Houtte
Journal:  Antimicrob Agents Chemother       Date:  2011-08-08       Impact factor: 5.191

4.  An Evolutionary Model-Based Approach To Quantify the Genetic Barrier to Drug Resistance in Fast-Evolving Viruses and Its Application to HIV-1 Subtypes and Integrase Inhibitors.

Authors:  Kristof Theys; Pieter J K Libin; Kristel Van Laethem; Ana B Abecasis
Journal:  Antimicrob Agents Chemother       Date:  2019-07-25       Impact factor: 5.191

5.  Effect of natural polymorphisms in the HIV-1 CRF02_AG protease on protease inhibitor hypersusceptibility.

Authors:  André F A Santos; Denis M Tebit; Matthew S Lalonde; Ana B Abecasis; Annette Ratcliff; Ricardo J Camacho; Ricardo S Diaz; Ottmar Herchenröder; Marcelo A Soares; Eric J Arts
Journal:  Antimicrob Agents Chemother       Date:  2012-02-13       Impact factor: 5.191

6.  Viral Genetic Diversity and Polymorphisms in a Cohort of HIV-1-Infected Patients Eligible for Initiation of Antiretroviral Therapy in Abuja, Nigeria.

Authors:  Karidia Diallo; Du-Ping Zheng; Erin K Rottinghaus; Orji Bassey; Chunfu Yang
Journal:  AIDS Res Hum Retroviruses       Date:  2015-02-05       Impact factor: 2.205

7.  Estimating the individualized HIV-1 genetic barrier to resistance using a nelfinavir fitness landscape.

Authors:  Kristof Theys; Koen Deforche; Gertjan Beheydt; Yves Moreau; Kristel van Laethem; Philippe Lemey; Ricardo J Camacho; Soo-Yon Rhee; Robert W Shafer; Eric Van Wijngaerden; Anne-Mieke Vandamme
Journal:  BMC Bioinformatics       Date:  2010-08-03       Impact factor: 3.169

8.  Genetic determinants in HIV-1 Gag and Env V3 are related to viral response to combination antiretroviral therapy with a protease inhibitor.

Authors:  Sarah K Ho; Elena E Perez; Stephanie L Rose; Roxana M Coman; Amanda C Lowe; Wei Hou; Changxing Ma; Robert M Lawrence; Ben M Dunn; John W Sleasman; Maureen M Goodenow
Journal:  AIDS       Date:  2009-08-24       Impact factor: 4.177

9.  Antiretroviral drug susceptibility among drug-naive adults with recent HIV infection in Rakai, Uganda.

Authors:  Susan H Eshleman; Oliver Laeyendecker; Neil Parkin; Wei Huang; Colombe Chappey; Agnes C Paquet; David Serwadda; Steven J Reynolds; Noah Kiwanuka; Thomas C Quinn; Ronald Gray; Maria Wawer
Journal:  AIDS       Date:  2009-04-27       Impact factor: 4.177

10.  Novel recombinant virus assay for measuring susceptibility of human immunodeficiency virus type 1 group M subtypes to clinically approved drugs.

Authors:  Kris Covens; Nathalie Dekeersmaeker; Yoeri Schrooten; Jan Weber; Dominique Schols; Miguel E Quiñones-Mateu; Anne-Mieke Vandamme; Kristel Van Laethem
Journal:  J Clin Microbiol       Date:  2009-04-29       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.